Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal.

This article is protected by copyright. All rights reserved.
PMID: 29733466 [PubMed - as supplied by publisher]

Source: Clinical Prostate Cancer - May 7, 2018 Category: Cancer & Oncology Authors: Chen L, Cao H, Yu C, Feng Y Tags: Fundam Clin Pharmacol Source Type: research